Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00770120 · OUTCOME

Response

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery · Source last updated 2020-03-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of overall response rate
Interval / dispersion
95% Confidence Interval
Time frame
Every 8 weeks until disease progression, up to 3 years.

What was measured

A response was defined as either a confirmed or unconfirmed complete or partial responses as defined by RECIST. A complete response (CR) was defined as the disappearance of all disease. A partial response (PR) was defined as a \>= 30% decrease in the sum of longest diameters of target lesions. A CR or PR was considered confirmed if two consecutive determinations were made at least 4 weeks apart.

Groups in this outcome

Everolimus

Daily oral Everolimus 10 mg/day everolimus

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Everolimus45

Reported measurements

Source class 1
Values in percentage of overall response rate · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Everolimus2Not reported012Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        12
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      45
    units
    Participants
description
A response was defined as either a confirmed or unconfirmed complete or partial responses as defined by RECIST. A complete response (CR) was defined as the disappearance of all disease. A partial response (PR) was defined as a \>= 30% decrease in the sum of longest diameters of target lesions. A CR or PR was considered confirmed if two consecutive determinations were made at least 4 weeks apart.
dispersion Type
95% Confidence Interval
groups
  1. description
    Daily oral Everolimus 10 mg/day everolimus
    id
    OG000
    title
    Everolimus
param Type
NUMBER
reporting Status
POSTED
time Frame
Every 8 weeks until disease progression, up to 3 years.
title
Response
type
SECONDARY
unit Of Measure
percentage of overall response rate

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice